Dr. Priyom Bose

Feature Writer

B.Sc. Botany, M.Sc. Plant Biology and Biotechnology, Ph.D. Plant Biology and Biotechnology

Priyom holds a Ph.D. in Plant Biology and Biotechnology from the University of Madras, India. She is an active researcher and an experienced science writer. Priyom has also co-authored several original research articles that have been published in reputed peer-reviewed journals. She is also an avid reader and an amateur photographer.

Articles from Priyom

Can surveillance of SARS-CoV-2 be conducted through aircraft wastewater analysis?

Research investigates the behavior of air travelers, especially those who had flown during the pandemic.

6 Oct 2022

Study investigates associations between potential endocrine-disrupting chemicals and female fertility

About one in six women of reproductive age face difficulties in conceiving or carrying a pregnancy to term. Although there has been a global increase in the use of assisted reproductive technologies (ARTs), the success rate of live birth has remained almost the same.

3 Oct 2022

A case for updating COVID vaccines with beta variant spike sequences

A recent Nature Communications study has discussed preclinical and clinical data on COVID-19 vaccine antigens that could be utilized to develop effective booster vaccines.

3 Oct 2022

Novel peanut-specific human IgE monoclonal antibodies may uncover new therapeutic targets for peanut allergy

A recent Frontiers in Immunology journal study by University of North Carolina at Chapel Hill and Vanderbilt University researchers has created an in vitro system to determine potential therapeutics targeting sensitized effector cells based on human, allergen-specific, Immunoglobulin E (IgE) monoclonal antibodies (mAbs).

2 Oct 2022

Broadly neutralizing antibodies are the blueprint for variant-proof, pansarbecovirus vaccines

A recent Nature Reviews Immunology study has summarized the efficacy of neutralizing antibodies that target four main regions of the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), namely, the receptor-binding domain (RBD) in the S1 subunit, the fusion peptide region in the S2 subunit, the stem helix region, and the N-terminal domain.

2 Oct 2022